North Dakota State Investment Board Buys New Stake in United Therapeutics Corporation $UTHR

North Dakota State Investment Board bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,564 shares of the biotechnology company’s stock, valued at approximately $762,000.

Other large investors have also recently bought and sold shares of the company. AE Wealth Management LLC increased its holdings in United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC grew its holdings in shares of United Therapeutics by 194.7% during the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock worth $1,888,000 after purchasing an additional 2,975 shares during the last quarter. Optimize Financial Inc purchased a new position in shares of United Therapeutics during the third quarter worth about $444,000. Tobam grew its holdings in shares of United Therapeutics by 183.9% during the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after purchasing an additional 4,953 shares during the last quarter. Finally, Perpetual Ltd purchased a new position in shares of United Therapeutics during the fourth quarter worth about $1,059,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $567.31, for a total transaction of $5,673,100.00. Following the completion of the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,708,543.56. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Nilda Mesa sold 258 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $581.93, for a total transaction of $150,137.94. Following the sale, the director owned 5,028 shares of the company’s stock, valued at $2,925,944.04. This trade represents a 4.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 542,113 shares of company stock worth $301,914,315 over the last three months. 8.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on UTHR shares. Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Bank of America raised their price objective on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. Raymond James Financial started coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective on the stock. Royal Bank Of Canada dropped their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Performance

Shares of UTHR opened at $563.93 on Thursday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The company has a market capitalization of $23.94 billion, a price-to-earnings ratio of 20.82, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60. The firm has a 50-day simple moving average of $562.18 and a 200-day simple moving average of $510.32.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the company posted $6.63 EPS. United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 27.07 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.